Valisure sues U.S. Pharmacopeia over alleged false statements on testing methods
Testing lab Valisure has filed a lawsuit accusing U.S. Pharmacopeia of making misleading claims about its drug-safety testing procedures.
Valisure, a laboratory that has previously clashed with regulators over drug impurities, alleges that the U.S. Pharmacopeia (USP) falsely described its testing methods as unvalidated and potentially misleading. The suit contends USP’s 2023 white paper suggested Valisure’s approach could cause unnecessary public concern. Valisure argues USP made these statements to bolster confidence in its own standards-setting system, which it says financially benefits from the portrayal.
Why it matters
The case could shape how drug-testing labs and standards organizations communicate about safety, affecting public trust.
In this story
